


Claims:

1. A compound of formula (I):




wherein:

- 5 R_1 is H, or C_{1-4} alkyl, halo, halo C_{1-4} alkyl, CN, C_{1-4} alkoxy, halo C_{1-4} alkoxy;
- R_2 is H, C_{1-4} alkyl, C_{3-4} spiro carbocycly, halo C_{1-4} alkyl or halo;
- R_3 is H, C_{1-4} alkyl, halo C_{1-4} alkyl, halo; or R_3 is absent;
- R_{13} is H, C_{1-4} alkyl, halo C_{1-4} alkyl, halo; or R_{13} is absent;
- 10 A is a 5 or 6 membered saturated or unsaturated heterocycle, with at least one O atom; which heterocycle is optionally fused with a cyclopropyl group to form a tricycle when considered together with the phenyl;
- X is C or N;
- Y is C or N;
- R_4 is C_{1-4} alkyl;
- 15 R_5 is H, Deuterium, C_{1-4} alkyl;
- or R_4 and R_5 can be fused to form C_{3-4} spiro carbocycly;
- wherein R_2 and R_3 may be attached to the same or a different ring atom; and wherein R_2 may be attached to a fused ring atom;

or a pharmaceutically acceptable salt and/or solvate thereof.

2 The compound according to claim 1, which is:



wherein

R_1 is H, or C_{1-4} alkyl, halo, halo C_{1-4} alkyl, CN, C_{1-4} alkoxy, halo C_{1-4} alkoxy;

5 R_2 is H, C_{1-4} alkyl, C_{3-4} spiro carbocycly, halo C_{1-4} alkyl or halo;

R_3 is H, C_{1-4} alkyl, halo C_{1-4} alkyl, halo;

A is a 5 or 6 membered saturated or unsaturated heterocycle, with at least one O atom; which heterocycle is optionally fused with a cyclopropyl group to form a tricycle when considered together with the phenyl;

10 X is C or N;

Y is C or N;

R_4 is C_{1-4} alkyl;

R_5 is H, Deuterium, C_{1-4} alkyl;

or R_4 and R_5 can be fused to form C_{3-4} spiro carbocycly;


15 wherein R_2 and R_3 may be attached to the same or a different ring atom;

and wherein R_2 may be attached to a fused ring atom;

or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 1 or claim 2, wherein R_1 is H or methyl.

4. The compound according to any one of claims 1 to 3, wherein A is a 5 membered saturated or unsaturated heterocycle, with at least one O atom; which heterocycle is optionally fused with a cyclopropyl group to form a tricycle when considered together with the phenyl.
5. The compound according to any one of claims 1 to 3, wherein A is a 6 membered saturated or unsaturated heterocycle, with at least one O atom; which heterocycle is optionally fused with a cyclopropyl group to form a tricycle when considered together with the phenyl.
6. The compound according to any one of claims 1 to 5, wherein the ring A is dihydrofuran or dihydropyran.
7. The compound according to any one of claims 1 to 6, wherein R_2 is H, methyl or a C_3 spiro group.
8. The compound according to any one of claims 1 to 7, wherein R_3 is H or methyl.
9. The compound according to any one of claims 1 to 8, wherein R_{13} is H, F or methyl.
10. The compound according to any one of claims 1 to 9, wherein X is C and Y is C.
11. The compound according to any one of claims 1 to 9, wherein X is C and Y is N.
12. The compound according to any one of claims 1 to 9, wherein X is N and Y is N.
13. The compound according to any one of claims 1 to 12, wherein R_4 is methyl or ethyl.
14. The compound according to any one of claims 1 to 13, wherein R_5 is H or methyl.
15. The compound according to any one of claims 1 to 14, wherein R_4 and R_5 have the stereochemical arrangement:



16. A compound according to claim 1 selected from the group consisting of:
 - (5R)-3-[4-(1,3-dihydro-2-benzofuran-4-yloxy)phenyl]-5-methyl-2,4-imidazolidinedione;
 - (5R)-5-methyl-3-[4-[(3-methyl-1,2-benzisoxazol-4-yl)oxy]phenyl]-2,4-imidazolidinedione;
 - (5R)-3-[4-[(3,6-dimethyl-1,2-benzisoxazol-4-yl)oxy]phenyl]-5-methyl-2,4-imidazolidinedione;
 - 5,5-dimethyl-3-[4-[(3-methyl-1,2-benzisoxazol-4-yl)oxy]phenyl]-2,4-imidazolidinedione;

- (5R)-5-ethyl-3-{6-[(3-ethyl-1,2-benzisoxazol-4-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione;
- (5R)-5-ethyl-3-{6-[(3-(1-methylethyl)-1,2-benzisoxazol-4-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione;
- (5R)-3-{4-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]phenyl}-5-methyl-2,4-imidazolidinedione;
- (5R)-3-{6-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-3-pyridinyl}-5-methyl-2,4-imidazolidinedione;
- 5 (5R)-3-{6-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-3-pyridinyl}-5-ethyl-2,4-imidazolidinedione;
- (5R)-3-{2-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-5-pyrimidinyl}-5-ethyl-2,4-imidazolidinedione;
- 7-{6-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-3-pyridinyl}-5,7-diazaspiro[3.4]octane-6,8-dione;
- 10 6-{6-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-3-pyridinyl}-4,6-diazaspiro[2.4]heptane-5,7-dione;
- 3-{6-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-3-pyridinyl}-5,5-dimethyl-2,4-imidazolidinedione;
- (5R)-3-{2-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-5-pyrimidinyl}-5-(1,1-dimethylethyl)-2,4-imidazolidinedione;
- 15 (5R)-5-ethyl-3-[6-(spiro[1-benzofuran-3,1'-cyclopropan]-4-yloxy)-3-pyridinyl]-2,4-imidazolidinedione;
- 5,5-dimethyl-3-[6-(spiro[1-benzofuran-3,1'-cyclopropan]-4-yloxy)-3-pyridinyl]-2,4-imidazolidinedione;
- (5R)-5-ethyl-5-methyl-3-[6-(spiro[1-benzofuran-3,1'-cyclopropan]-4-yloxy)-3-pyridinyl]-2,4-imidazolidinedione;
- 20 (5R)-5-ethyl-3-{6-[(3S/R)-3-methyl-1,3-dihydro-2-benzofuran-4-yl]oxy}-3-pyridinyl}-2,4-imidazolidinedione (diastereoisomeric mixture);
- (5R)-5-ethyl-3-{6-[(3-methyl-1,3-dihydro-2-benzofuran-4-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione (diastereoisomers 1 and 2);
- (5R)-5-ethyl-3-{6-[(3-ethyl-1,3-dihydro-2-benzofuran-4-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione (distereoisomeric mixture);
- 25 (5R)-5-ethyl-3-{6-[(3-ethyl-1,3-dihydro-2-benzofuran-4-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione (diastereoisomers 1 and 2);
- 5,5-dimethyl-3-{6-[(3-methyl-3,4-dihydro-2H-chromen-5-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione (racemic mixture);
- 30 5,5-dimethyl-3-{6-[(3-methyl-3,4-dihydro-2H-chromen-5-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione (enantiomers 1 and enantiomer 2);
- 5,5-dimethyl-3-{6-[(1a-methyl-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-7-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione (racemic mixture);

- 5,5-dimethyl-3-{6-[(1a-methyl-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-7-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione (enantiomer 1 and enantiomer 2);
- (5R)-5-ethyl-5-methyl-3-[6-(1H-spiro[2-benzopyran-4,1'-cyclopropan]-5-yloxy)-3-pyridinyl]-2,4-imidazolidinedione;
- 5 3-{2-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-5-pyrimidinyl}-5,5-dimethyl-2,4-imidazolidinedione;
- (5R)-3-{2-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-5-pyrimidinyl}-5-(1-methylethyl)-2,4-imidazolidinedione;
- (5R)-3-{6-[(2,2-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-3-pyridinyl}-5-ethyl-2,4-imidazolidinedione;
- 10 5,5-dimethyl-3-[6-(1H-spiro[2-benzopyran-4,1'-cyclopropan]-5-yloxy)-3-pyridinyl]-2,4-imidazolidinedione;
- (5R)-3-[2-(2,3-dihydrospiro[chromene-4,1'-cyclopropan]-5-yloxy)-5-pyrimidinyl]-5-ethyl-5-methyl-2,4-imidazolidinedione;
- 5,5-dimethyl-3-{6-[(4-methyl-3,4-dihydro-2H-chromen-5-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione
- 15 (racemate mixture, enantiomer 1, enantiomer 2);
- (5R)-5-ethyl-5-methyl-3-{6-[(3-methyl-3,4-dihydro-2H-chromen-5-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione (diastereoisomeric mixture, diastereoisomer 1, diastereoisomer 2);
- (5R)-5-ethyl-5-methyl-3-[6-(1,1a,2,7b-tetrahydrocyclopropa[c]chromen-7-yloxy)-3-pyridinyl]-2,4-imidazolidinedione (diastereoisomeric mixture, diastereoisomer 1, diastereoisomer 2);
- 20 3-{6-[(3-ethyl-1,3-dihydro-2-benzofuran-4-yl)oxy]-3-pyridinyl}-5,5-dimethyl-2,4-imidazolidinedione (racemate mixture, enantiomer 1, enantiomer 2);
- (5R)-5-ethyl-5-methyl-3-[2-(4-methylchroman-5-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione
- (diastereoisomeric mixture, diastereoisomer 1, diastereoisomer 2);
- (5R)-5-ethyl-5-methyl-3-[2-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione;
- 25 (5R)-3-[2-(3,3-dimethylisochroman-5-yl)oxypyrimidin-5-yl]-5-ethyl-5-methyl-imidazolidine-2,4-dione;
- (5R)-5-ethyl-5-methyl-3-[2-(7-methylspiro[1H-isobenzofuran-3,1'-cyclobutane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione;
- (5R)-5-ethyl-5-methyl-3-{2-[(3,3,7-trimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-5-pyrimidinyl}-2,4-imidazolidinedione;
- 30 (5R)-3-{2-[(2,2-difluoro-7-methyl-1,3-benzodioxol-4-yl)oxy]-5-pyrimidinyl}-5-ethyl-5-methyl-2,4-imidazolidinedione;

(5R)-3-{2-[(2,2-difluoro-1,3-benzodioxol-4-yl)oxy]-5-pyrimidinyl}-5-ethyl-5-methyl-2,4-imidazolidinedione;

(5R)-5-ethyl-5-methyl-3-{2-[(2,4,4-trimethyl-4H-3,1-benzoxazin-5-yl)oxy]-5-pyrimidinyl}-2,4-imidazolidinedione;

5 5,5-dimethyl-3-[2-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione;

3-[2-(3,3-dimethylisochroman-5-yl)oxypyrimidin-5-yl]-5,5-dimethyl-imidazolidine-2,4-dione;

5,5-dimethyl-3-[2-(7-methylspiro[1H-isobenzofuran-3,1'-cyclobutane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione;

10 (5R)-5-ethyl-3-[2-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione;

(5R)-5-ethyl-3-[6-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxy-3-pyridyl]imidazolidine-2,4-dione;

15 (5R)-5-ethyl-3-{6-[(3,3,7-trimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione;

(5R)-5-ethyl-3-{2-[(3,3,7-trimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-5-pyrimidinyl}-2,4-imidazolidinedione;

(5R)-5-ethyl-5-methyl-3-[6-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxy-3-pyridyl]imidazolidine-2,4-dione;

20 (5R)-3-[6-(3,3-dimethylisochroman-5-yl)oxy-3-pyridyl]-5-ethyl-5-methyl-imidazolidine-2,4-dione;

(5R)-3-[6-[(3,3-diethyl-1H-isobenzofuran-4-yl)oxy]-3-pyridyl]-5-ethyl-5-methyl-imidazolidine-2,4-dione;

(5R)-5-ethyl-5-methyl-3-[6-[(2,4,4-trimethyl-3,1-benzoxazin-5-yl)oxy]-3-pyridyl]imidazolidine-2,4-dione;

(5R)-3-{6-[(3,3-dimethyl-1,3-dihydro-2-benzofuran-4-yl)oxy]-3-pyridinyl}-5-ethyl-5-methyl-2,4-imidazolidinedione; and

25 5,5-dimethyl-3-[6-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxy-3-pyridyl]imidazolidine-2,4-dione.

17. The compound according to claim 16, selected from the group consisting of:

(5R)-3-[4-(1,3-dihydro-2-benzofuran-4-yloxy)phenyl]-5-methyl-2,4-imidazolidinedione;

(5R)-5-methyl-3-{4-[(3-methyl-1,2-benzisoxazol-4-yl)oxy]phenyl}-2,4-imidazolidinedione;

30 (5R)-3-{4-[(3,6-dimethyl-1,2-benzisoxazol-4-yl)oxy]phenyl}-5-methyl-2,4-imidazolidinedione;

5,5-dimethyl-3-{4-[(3-methyl-1,2-benzisoxazol-4-yl)oxy]phenyl}-2,4-imidazolidinedione;

(5R)-5-ethyl-3-{6-[(3-ethyl-1,2-benzisoxazol-4-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione;

- (5R)-5-ethyl-3-(6-([3-(1-methylethyl)-1,2-benzisoxazol-4-yl]oxy)-3-pyridinyl)-2,4-imidazolidinedione;
- (5R)-3-{4-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]phenyl}-5-methyl-2,4-imidazolidinedione;
- (5R)-3-{6-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-3-pyridinyl}-5-methyl-2,4-imidazolidinedione;
- 5 (5R)-3-{6-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-3-pyridinyl}-5-ethyl-2,4-imidazolidinedione;
- (5R)-3-{2-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-5-pyrimidinyl}-5-ethyl-2,4-imidazolidinedione;
- 7-{6-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-3-pyridinyl}-5,7-diazaspiro[3.4]octane-6,8-dione;
- 6-{6-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-3-pyridinyl}-4,6-diazaspiro[2.4]heptane-5,7-dione;
- 10 3-{6-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-3-pyridinyl}-5,5-dimethyl-2,4-imidazolidinedione;
- (5R)-3-{2-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-5-pyrimidinyl}-5-(1,1-dimethylethyl)-2,4-imidazolidinedione;
- 15 (5R)-5-ethyl-3-[6-(spiro[1-benzofuran-3,1'-cyclopropan]-4-yloxy)-3-pyridinyl]-2,4-imidazolidinedione;
- 5,5-dimethyl-3-[6-(spiro[1-benzofuran-3,1'-cyclopropan]-4-yloxy)-3-pyridinyl]-2,4-imidazolidinedione;
- (5R)-5-ethyl-5-methyl-3-[6-(spiro[1-benzofuran-3,1'-cyclopropan]-4-yloxy)-3-pyridinyl]-2,4-imidazolidinedione;
- (5R)-5-ethyl-3-(6-([(3S/R)-3-methyl-1,3-dihydro-2-benzofuran-4-yl]oxy)-3-pyridinyl)-2,4-imidazolidinedione (diastereoisomeric mixture);
- 20 (5R)-5-ethyl-3-{6-[(3-methyl-1,3-dihydro-2-benzofuran-4-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione (diastereoisomers 1 and 2);
- (5R)-5-ethyl-3-{6-[(3-ethyl-1,3-dihydro-2-benzofuran-4-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione (distereoisomeric mixture);
- 25 (5R)-5-ethyl-3-{6-[(3-ethyl-1,3-dihydro-2-benzofuran-4-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione (diastereoisomers 1 and 2);
- 5,5-dimethyl-3-{6-[(3-methyl-3,4-dihydro-2H-chromen-5-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione (racemic mixture);
- 5,5-dimethyl-3-{6-[(3-methyl-3,4-dihydro-2H-chromen-5-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione (enantiomers 1 and enantiomer 2);
- 30 5,5-dimethyl-3-{6-[(1a-methyl-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-7-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione (racemic mixture);

5,5-dimethyl-3-{6-[(1a-methyl-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-7-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione (enantiomer 1 and enantiomer 2);

(5R)-5-ethyl-5-methyl-3-[6-(1H-spiro[2-benzopyran-4,1'-cyclopropan]-5-yloxy)-3-pyridinyl]-2,4-imidazolidinedione;

- 5 3-{2-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-5-pyrimidinyl}-5,5-dimethyl-2,4-imidazolidinedione;

(5R)-3-{2-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-5-pyrimidinyl}-5-(1-methylethyl)-2,4-imidazolidinedione;

(5R)-3-{6-[(2,2-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-3-pyridinyl}-5-ethyl-2,4-imidazolidinedione;

- 10 5,5-dimethyl-3-[6-(1H-spiro[2-benzopyran-4,1'-cyclopropan]-5-yloxy)-3-pyridinyl]-2,4-imidazolidinedione;

(5R)-3-[2-(2,3-dihydrospiro[chromene-4,1'-cyclopropan]-5-yloxy)-5-pyrimidinyl]-5-ethyl-5-methyl-2,4-imidazolidinedione;

- 15 5,5-dimethyl-3-{6-[(4-methyl-3,4-dihydro-2H-chromen-5-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione (racemate mixture, enantiomer 1, enantiomer 2);

(5R)-5-ethyl-5-methyl-3-{6-[(3-methyl-3,4-dihydro-2H-chromen-5-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione (diastereoisomeric mixture, diastereoisomer 1, diastereoisomer 2);

(5R)-5-ethyl-5-methyl-3-[6-(1,1a,2,7b-tetrahydrocyclopropa[c]chromen-7-yloxy)-3-pyridinyl]-2,4-imidazolidinedione (diastereoisomeric mixture, diastereoisomer 1, diastereoisomer 2); and

- 20 3-{6-[(3-ethyl-1,3-dihydro-2-benzofuran-4-yl)oxy]-3-pyridinyl}-5,5-dimethyl-2,4-imidazolidinedione (racemate mixture, enantiomer 1, enantiomer 2).

18. Use of a compound according to any one of claims 1 to 17 in the manufacture of a medicament for the prophylaxis or treatment of hearing disorders, schizophrenia, bipolar disorder or sleep disorders.

19. The use according to claim 18 in manufacture of a medicament for the the prophylaxis or
25 treatment of hearing disorders.

20. The use according to claim 18 or claim 19, wherein the hearing disorder is selected from the group consisting of auditory neuropathy, auditory processing disorder, hearing loss, which includes sudden hearing loss, noise induced hearing loss, substance-induced hearing loss, hearing loss in adults over 60 (presbycusis), and tinnitus.

- 30 21. The use according to claim 18 or claim 19, wherein the hearing disorder is hearing loss.


22. The use according to claim 18 or claim 19, wherein the hearing disorder is tinnitus.

23. The use according to claim 18, in the manufacture of a medicament for the prophylaxis or treatment of schizophrenia.


24. A pharmaceutical composition comprising a compound according to any one of claims 1 to 17 and a pharmaceutically acceptable carrier or excipient.

5 25. A compound selected from:


spiro[1-benzofuran-3,1'-cyclopropan]-4-ol



7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-ol




10 3,3,7-trimethyl-2,3-dihydro-1-benzofuran-4-ol



or a salt thereof.

26. A compound selected from:




15 wherein:

X is C or N;

Y is C or N; and


the group W is selected from:



or a salt thereof.

Claims:

1. A compound of formula (I):



wherein:


- 5 R₁ is H, or C₁₋₄alkyl, halo, haloC₁₋₄alkyl, CN, C₁₋₄alkoxy, haloC₁₋₄alkoxy;
- R₂ is H, C₁₋₄alkyl, C₃₋₄ spiro carbocycly, haloC₁₋₄alkyl or halo;
- R₃ is H, C₁₋₄alkyl, haloC₁₋₄alkyl, halo; or R₃ is absent;
- R₁₃ is H, C₁₋₄alkyl, haloC₁₋₄alkyl, halo; or R₁₃ is absent;
- 10 A is a 5 or 6 membered saturated or unsaturated heterocycle, with at least one O atom; which heterocycle is optionally fused with a cyclopropyl group to form a tricycle when considered together with the phenyl;
- X is C or N;
- Y is C or N;
- R₄ is C₁₋₄ alkyl;
- 15 R₅ is H, Deuterium, C₁₋₄ alkyl;
- or R₄ and R₅ can be fused to form C₃₋₄ spiro carbocycly;
- wherein R₂ and R₃ may be attached to the same or a different ring atom; and wherein R₂ may be attached to a fused ring atom;
- or a pharmaceutically acceptable salt and/or solvate thereof.


2 The compound according to claim 1, which is:

5

10

15





wherein

R₁ is H, or C₁₋₄alkyl, halo, haloC₁₋₄alkyl, CN, C₁₋₄alkoxy, haloC₁₋₄alkoxy;

R₂ is H, C₁₋₄alkyl, C₃₋₄ spiro carbocycly, haloC₁₋₄alkyl or halo;

5 R₃ is H, C₁₋₄alkyl, haloC₁₋₄alkyl, halo;

A is a 5 or 6 membered saturated or unsaturated heterocycle, with at least one O atom; which heterocycle is optionally fused with a cyclopropyl group to form a tricycle when considered together with the phenyl;

X is C or N;

10 Y is C or N;

R₄ is C₁₋₄ alkyl;

R₅ is H, Deuterium, C₁₋₄ alkyl;

or R₄ and R₅ can be fused to form C₃₋₄ spiro carbocycly;

wherein R₂ and R₃ may be attached to the same or a different ring atom;


15 and wherein R₂ may be attached to a fused ring atom;

or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 1 or claim 2, wherein R₁ is H or methyl.

4. The compound according to any one of claims 1 to 3, wherein A is a 5 membered saturated or unsaturated heterocycle, with at least one O atom; which heterocycle is optionally fused with a cyclopropyl group to form a tricycle when considered together with the phenyl.
5. The compound according to any one of claims 1 to 3, wherein A is a 6 membered saturated or unsaturated heterocycle, with at least one O atom; which heterocycle is optionally fused with a cyclopropyl group to form a tricycle when considered together with the phenyl.
6. The compound according to any one of claims 1 to 5, wherein the ring A is dihydrofuran or dihydropyran.
7. The compound according to any one of claims 1 to 6, wherein R_2 is H, methyl or a C_3 spiro group.
8. The compound according to any one of claims 1 to 7, wherein R_3 is H or methyl.
9. The compound according to any one of claims 1 to 8, wherein R_{13} is H, F or methyl.

10. The compound according to any one of claims 1 to 9, wherein X is C and Y is C.
11. The compound according to any one of claims 1 to 9, wherein X is C and Y is N.
12. The compound according to any one of claims 1 to 9, wherein X is N and Y is N.
13. The compound according to any one of claims 1 to 12, wherein R_4 is methyl or ethyl.
- 5 14. The compound according to any one of claims 1 to 13, wherein R_5 is H or methyl.
15. The compound according to any one of claims 1 to 14, wherein R_4 and R_5 have the stereochemical arrangement:



16. The compound according to any one of claims 1 to 15, for use as a medicament.
- 10 17. The compound according to claim 16, for use in the prophylaxis or treatment of hearing disorders, schizophrenia, bipolar disorder, epilepsy or sleep disorders.

18. The compound according to claim 16 or claim 17, for use in conjunction with a further pharmaceutically active agent.

19. A method for the prophylaxis or treatment of hearing disorders, schizophrenia, bipolar disorder, epilepsy or sleep disorders by administering to a subject a compound according to any one of claims 1 to


15.

20. Use of a compound according to any one of claims 1 to 15 in the manufacture of a medicament for the prophylaxis or treatment of hearing disorders, schizophrenia, bipolar disorder, epilepsy or sleep disorders.


21. A pharmaceutical composition comprising a compound according to any one of claims 1 to 15 and a pharmaceutically acceptable carrier or excipient.

22. A compound selected from:

spiro[1-benzofuran-3,1'-cyclopropan]-4-ol




7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-ol




; and

3,3,7-trimethyl-2,3-dihydro-1-benzofuran-4-ol



or a salt thereof.

23. A compound selected from:







5 wherein:

X is C or N;

Y is C or N; and

the group W is selected from:



10 or a salt thereof.